Exos Asset Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Exos Asset Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$356K	Sell	36,318 -10,544	-23%	-$103K	0.19%	124
2022 Q1	$456K	Buy	46,862 +1,562	+3%	+$15.2K	0.2%	132
2021 Q4	$439K	Hold	45,300	–	–	0.23%	135
2021 Q3	$438K	Hold	45,300	–	–	0.23%	137
2021 Q2	$441K	Buy	+45,300	New	+$445K	0.23%	136

Other funds holding EBAC

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Exos Asset Management's EBAC Position: Q2 2022 in Review

Exos Asset Management reduced its European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) stake by 23% in Q2 2022, selling an estimated $103K and leaving 36,318 shares worth $356K. The position accounts for 0.19% of the portfolio, ranked #124.

Exos Asset Management first reported a position in EBAC in Q2 2021 and has held it in 5 quarters since. The position peaked at $456K in Q1 2022. 46 funds tracked by Wall St. Rank hold EBAC as of Q2 2022.

Exos Asset Management held 36,318 shares of European Biotech Acquisition Corp. Class A Ordinary Shares worth $356K as of Q2 2022.
Exos Asset Management sold 10,544 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q2 2022, an estimated $103K.
European Biotech Acquisition Corp. Class A Ordinary Shares made up 0.19% of Exos Asset Management's portfolio in Q2 2022, its #124 holding.
Exos Asset Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and has held it in 5 quarters since.
Exos Asset Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $456K in Q1 2022.
46 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q2 2022.

Based on Exos Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.